No Data
No Data
Coherus Biosciences CCO Resigns After UDENYCA Divestiture
Sector Update: Health Care
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million
Express News | Accord Biopharma, Inc. Announces Completion of Udenyca® (Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
Express News | Coherus Completes Strategic Transformation With Successful Divestiture of Udenyca® Franchise
Coherus Completes Strategic Transformation With Successful Divestiture of UDENYCA Franchise
CoolWaterCoolWater : Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7